Non Small Cell Lung Cancer News and Research

RSS

Non-Small Cell Lung Cancers are a group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Non-small cell lung cancer is the most common kind of lung cancer.

MAPK pathway mutations can provide “precision” treatment targets for head and neck cancer

About one-fifth of often deadly head and neck cancers harbor genetic mutations in a pathway that is key to normal cell growth, and scientists report those mutations, which enable abnormal cancer cell growth, can also make the cancer vulnerable.

28 Apr 2022

New data may change the standard of care for patients with advanced non-small cell lung cancer

The phase 2 clinical trial of a multi-center study known as the COAST clinical trial has demonstrated improved outcomes using immunotherapy combinations for patients with unresectable stage III non-small cell lung cancer, according to researchers at Yale Cancer Center and participating organizations.

25 Apr 2022

Drug used to treat lung cancer could help improve survival rates for bladder cancer patients

Scientists from the University of Sheffield have discovered a drug already used to treat lung cancer could help to improve survival rates for bladder cancer patients.

11 Apr 2022

Adding immunotherapy to chemotherapy before surgery improves outcomes for NSCLC patients

Adding the immunotherapy drug nivolumab to chemotherapy before surgery (neoadjuvant) for patients with operable non-small cell lung cancer (NSCLC) — the leading cause of cancer deaths worldwide — reduced the risk of recurrence of the cancer or death by more than one-third, according to results from the phase III CheckMate-816 trial.

11 Apr 2022

Study finds better immunotherapy response in lung cancer patients with genetic variant linked to autoimmune disease

A variant of the CTLA-4 gene associated with autoimmune disease was found to be more frequent in non-small cell lung cancer (NSCLC) patients who experienced an exceptionally high response to anti-PD-1 immunotherapy and higher immune-related side effects than in a comparable cohort of lung cancer patients and healthy individuals, according to data presented during the AACR Annual Meeting 2022, held April 8-13.

10 Apr 2022

NSCLC patients treated with KRAS G12C inhibitor sotorasib may receive long-term clinical benefit

Patients with non-small cell lung cancer (NSCLC) treated with the KRAS G12C inhibitor sotorasib (Lumakras) had a two-year overall survival rate of 32.5 percent, according to data from the CodeBreaK 100 clinical trial presented during the AACR Annual Meeting 2022, held April 8-13.

10 Apr 2022

City of Hope's late-breaking clinical trial data to be presented at AACR

Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States, will present late-breaking and clinical trial findings at this year's American Association for Cancer Research Annual Meeting, which begins today.

8 Apr 2022

New tactic to disrupt cancer repair mechanism could lead to a potential treatment strategy

While cancer therapies targeting specific genes or disease pathways have extended lives, they can also lead to highly resistant tumors when small reservoirs of cancer cells survive treatment, grow, and spread.

30 Mar 2022

Biomarker testing in lung cancer patients has increased in real-world clinical practice, study reveals

More than half of patients diagnosed with advanced non-small cell lung cancer (NSCLC) undergo biomarker testing, and this figure has increased over the last five years, reveal real-world data from a Spanish national registry study reported at the European Lung Cancer Congress, 30 March-2 April 2022.

23 Mar 2022

Researchers receive a combined $1 million grant to study RET-positive lung cancer

University of Colorado Cancer Center member Tejas Patil, MD, is one of three researchers to receive a combined $1 million grant from the Hamoui Foundation and LUNGevity Foundation to study RET-positive lung cancer.

21 Mar 2022

Zentalis contributes $1 million to SU2C Catalyst program for research into targeted cancer therapeutics

Stand Up To Cancer and Zentalis Pharmaceuticals, Inc. today announced that Zentalis will contribute $1 million to the SU2C Catalyst program to support research that investigates the use of certain small molecule inhibitors for treating a variety of cancer types.

15 Mar 2022

Salk professors receive $3 million Endeavor Award to support lung cancer research

Professors Reuben Shaw, Susan Kaech, Christian Metallo and Alan Saghatelian have received a 2022 Mark Foundation for Cancer Research Endeavor Award to support their research exploring the metabolic changes that help lung cancers develop.

11 Mar 2022

New, highly promising strategy to overcome a key cause of cancer deaths

A research team led by scientists at Albert Einstein College of Medicine has devised a novel and highly promising strategy for overcoming a key cause of cancer deaths: the ability of cancer cells to thrive in the face of chemotherapy drugs designed to destroy them.

7 Mar 2022

ESMO announces a new series of resources to guide physicians in oncological practice

ESMO, the leading professional organization for medical oncology, announces a new series of resources designed to guide physicians in areas of oncological practice not covered by guidelines, where current evidence is insufficient to evenly inform clinical decision-making.

28 Feb 2022

Treatment with Tumor Treating Fields triggers downstream anti-tumor cell response, study finds

Novocure announced that a new study published in the Journal of Clinical Investigation (JCI) finds treatment with Tumor Treating Fields (TTFields) mediated cell disruption activates the immune system and triggers an anti-tumor cell response that may be effectively used together with existing immunotherapy approaches in the treatment of solid tumors, with limited systemic toxicity.

25 Feb 2022

Researchers shows how ΔNp63 protein contributes to lung cancer development

Lung cancer is the second most common cancer in the U.S. and the No. 1 cause of cancer related death. Despite considerable progress in treatment options, most lung cancer patients have extremely poor outcomes with an average five-year survival rate of 21.7%.

12 Feb 2022

Lung cancer patients with coronary artery calcium burden have greater risk of cardiovascular events

Lung cancer patients with higher amounts of coronary artery calcium have an increased risk of an adverse cardiovascular event as a result of thoracic radiation therapy compared to patients with no coronary artery calcium.

11 Feb 2022

Study reveals seven major determinants of mortality risk for patients with COVD-19 and thoracic cancer

The risk of death for patients with SARS-CoV-2 infection and thoracic cancer is based on seven major determinants, according to research published in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer.

1 Feb 2022

Independent drug action responsible for greater clinical efficacy of combination cancer therapies

Independent drug action, not synergy nor additivity, accounted for the clinical efficacy of nearly all examined combination therapies involving immune checkpoint inhibitors in clinical trials, according to results from a retrospective analysis.

19 Jan 2022

Study demonstrates decreased lung cancer deaths with early detection

A recent, substantial decline in lung cancer deaths is associated with earlier diagnosis of lung cancer than in the past, supporting the need for increased use of screening to save lives, according to a Mount Sinai study published in JAMA Network Open in December.

18 Dec 2021